FY2025 Earnings Estimate for HIMS Issued By Leerink Partnrs

Hims & Hers Health, Inc. (NYSE:HIMS) – Analysts at Leerink Partnrs lifted their FY2025 earnings per share (EPS) estimates for Hims & Hers Health in a note issued to investors on Tuesday, November 5th. Leerink Partnrs analyst M. Cherny now expects that the company will earn $0.49 per share for the year, up from their prior forecast of $0.39. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.22 per share.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 11.67% and a net margin of 8.19%. The company had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. During the same quarter in the previous year, the business earned ($0.04) EPS. The company’s quarterly revenue was up 77.1% compared to the same quarter last year.

Several other research firms have also commented on HIMS. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Bank of America lifted their target price on Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Truist Financial upped their target price on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, July 18th. TD Cowen lifted their price target on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Finally, Needham & Company LLC initiated coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective for the company. Eight research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Hims & Hers Health Trading Up 0.9 %

Shares of NYSE HIMS opened at $23.62 on Thursday. Hims & Hers Health has a twelve month low of $6.58 and a twelve month high of $25.74. The firm has a 50-day moving average of $18.40 and a two-hundred day moving average of $18.29. The company has a market capitalization of $5.07 billion, a price-to-earnings ratio of 54.80 and a beta of 1.06.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in HIMS. Nisa Investment Advisors LLC boosted its position in Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares during the period. Quest Partners LLC grew its stake in Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after buying an additional 3,507 shares during the last quarter. CWM LLC raised its holdings in Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after acquiring an additional 1,054 shares during the period. Van ECK Associates Corp acquired a new position in Hims & Hers Health during the 2nd quarter worth $111,000. Finally, Amalgamated Bank boosted its holdings in Hims & Hers Health by 55.9% during the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after acquiring an additional 2,354 shares during the period. 63.52% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Hims & Hers Health news, insider Soleil Boughton sold 2,339 shares of the company’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $16.50, for a total value of $38,593.50. Following the transaction, the insider now directly owns 176,952 shares of the company’s stock, valued at $2,919,708. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Hims & Hers Health news, insider Soleil Boughton sold 2,339 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $16.50, for a total value of $38,593.50. Following the completion of the sale, the insider now directly owns 176,952 shares of the company’s stock, valued at $2,919,708. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the transaction, the chief executive officer now owns 33,502 shares in the company, valued at $487,789.12. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 854,547 shares of company stock worth $15,987,230. Corporate insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.